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This is not the end. It’s not even the beginning of the
end. But it is, perhaps, the end of the beginning.
Sir Winston Churchill
Immune reconstitution after hematopoietic stem
cell transplantation (HSCT) has been well studied
in the mouse and humans, and the relationship be-
tween delayed immune reconstitution and posttrans-
plant morbidity and mortality from infections and
relapse has been well documented [1]. Whereas
erythroid, myeloid, and platelet reconstitution occurs94in most cases in the first weeks after HSCT and is
primarily determined by engraftment of donor
HSCs, B cell, and especially T cell reconstitution
takes much longer, and recipients of allogeneic
HSCT can have an impaired T and B cell function
even years after their HSCT [2]. In recent years
a number of strategies to enhance posttransplant
immune reconstitution have been developed and
successfully tested in preclinical models. These
studies in experimental models mark ‘‘the end of
the beginning,’’ and in this article we will discuss
the first attempts to introduce these strategies in
clinical trials with HSCT recipients.Notch Signaling in Hematopoiesis: Implication for
Improving Stem Cell Transplantation
Irwin D. Bernstein, Colleen Delaney, Mari Dallas, Shelly Heimfeld, Barbara Varnum-Finney
Fred Hutchinson Cancer Research Center, Seattle, WashingtonThe factors governing hematopoietic stem/pro-
genitor cells are not well understood, but are thought
to result from an interplay between soluble factors
such as cytokines, and intercellular interactions, in-
cluding those with marrow stroma. These latter inter-
actions involve a number of evolutionary conserved
pathways known to govern cell fate decisions in
a wide variety of developing systems, such as theNotch
pathway. Studies of hematopoiesis have revealed a role
for Notch signalling in regulating early lymphoid
development, specifically in regulating T versus Bcell-fate decisions [3,4]. Although the physiologic
role of Notch signaling in regulating hematopoietic
stem cell fate decisions in vivo has been controversial,
in vitro studies have shown that enforced expression of
the constitutively active intracellular domain of
Notch1 inmurine hematopoietic stem cells (HSCs) in-
duces inhibition of myeloid differentiation, promotion
of early T cell differentiation, and enhanced genera-
tion of marrow repopulating cells [5]. Furthermore,
activation of endogenous Notch receptors using an
immobilized, engineered form of the Notch ligand
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also profoundly affected differentiation in a cytokine
context-dependent manner, including the promotion
of earlyT cell differentiation and generation of amulti-
log increase in the number of precursors with short-
term lymphoid and myeloid repopulating ability [6].
These findings suggest a potential role for Notch sig-
naling in regulating stem cell growth and differentia-
tion, and further suggest that compensatory effects,
in vivo such as those mediated by cytokines may
obscure such effects.
In this review, we will further address: (1) the role
of Notch signaling in hematopoietic stem/progenitor
cell self-renewal and differentiation in vivo, including
during nonhomeostatic states; and (2) mechanisms
whereby Notch signaling can mediate different cellu-
lar fates. These studies will address how quantitative
and qualitative differences in ligand type and density
lead to differential activation of specific Notch recep-
tors, in turn, differentially activating target genes and
self-renewal versus differentiation pathways. We willalso address (3) the potential for exploiting the
profound effects of Notch signaling ex vivo to generate
hematopoietic stem/progenitor cells to improve clini-
cal stem cell transplantation. In these studies of human
cord blood precursor cells, cultured with Delta1ext-IgG
led to an approximate 15-fold increase in the severe
combined immunodeficiency syndrome (SCID) repo-
poulating cell frequency and resulted in more rapid
engraftment compared to noncultured cells. Based
on these preclinical studies demonstrating enhanced
early engraftment of Delta-cultured cells, we have
developed clinically relevant methods for expanding
cord blood repopulating cells using Notch ligand
[7,8]. The potential efficacy of these expanded progen-
itors is currently being tested in a Phase I clinical trial,
in which patients receive cord blood progenitors that
were cultured with Delta1ext-IgG and a second, noncul-
tured cord blood unit. Promising results from initial
patients suggesting the ability to overcome the delayed
engraftment often encountered in patients undergoing
cord blood transplantation will be discussed.Enhanced Posttransplant T Cell Reconstitution With
Interleukin-7, Keratinocyte Growth Factor, and
Lymphoid Precursors
Gabrielle L. Goldberg, Johannes L. Zakrzewski, Marcel R.M. van den Brink
Memorial Sloan-Kettering Cancer Center, New York, New YorkInterleukin-7
IL-7 is produced by enterocytes and keratinocytes
as well as thymic and bone marrow stromal cells. It is
a 25-kDa glycoprotein that binds IL-7 receptor (IL-
7R), which comprises the common cytokine receptor
g-chain (gc) and the IL-7R a-chain (also known as
CD127). IL-7R is expressed by a variety of hematopoi-
etic cells including common lymphoid precursors,
developing B cells, triple negative and single positive
thymocytes, thymic dendritic cells, both CD41 and
CD81 peripheral T cells, gd T cells, and monocytes.
It is also expressed on nonhematopoietic cells includ-
ing keratinocytes and intestinal epithelial cells
(reviewed in [9]).
BothT andB cell development inmice require IL-7,
but IL-7 is not essential for normal B cell develop-
ment in humans. A defect in IL7Ra leads to SCID
and a complete lack of T cells [10]. In mouse models
of bone marrow transplantation, IL-7 augments
T cell reconstitution in syngeneic and allogeneicrecipients. This is because of improved thymopoiesis
and increased homeostatic proliferation of mature T
cells as well as decreased apoptosis of peripheral T cells
(Figure 1). Following IL-7 administration, T cell
Figure 1. IL-7, KGF and donor T/NK precursors enhance post-
transplant T cell reconstitution.
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unaffected [11]. Several studies have demonstrated
that graft-versus-host-disease (GVHD) is not exacer-
bated by IL-7 administration. However, at high doses
and with prolonged administration IL-7 may exacer-
bate GVHD when given in a T cell-replete setting
[12,13]. Finally, graft-versus-tumor (GVT) remains
intact following IL-7 adminstration and allogeneic
BMT [11].
Phase 1 clinical trials have been performed with
CYT 99 007 (Cytheris, Inc., Rockville, MD), a re-
combinant nonglycosylated form of human IL-7. Pa-
tients have been treated, in dose-escalation trials,
with subcutaneous CYT 99 007 in a dose range varying
from 3 to 60 mg/kg/dose (R. Buffet, personal commu-
nication). Toxicity effects were minimal and immuno-
logic efficacy was confirmed in these studies.
Following repeated doses of CYT 99 007, naı¨ve and
memory CD41 and CD81 T cells were elevated, as
were recent thymic emigrants (RTEs) [14]. As defined
by Ki67 and BCL-2, proliferation and survival of pe-
ripheral T cells were also enhanced with IL-7 admin-
istration. T cell expansion appeared to be more
profound in those patients that had lower baseline T
cell counts. This finding is consistent with the role of
IL-7 in homeostatic expansion. Further studies with
a less immunogenic and appropriately glycosylated
form of IL-7 (CYT107, Cytheris) are under way.
Keratinocyte Growth Factor (KGF)
KGF, also know as fibroblast growth factor 7
(FGF7), is primarily produced by cells of mesenchymal
origin and is an epithelial mitogen (summarized in
[15]). In the thymus, fibroblasts are the major source
of KGF [16]. Thymocyte subsets also produce KGF,
and its production increases as the thymocytes mature
[17]. FGFR2IIIb is the only known receptor for KGF,
and is expressed primarily by epithelial cells [15]. In the
thymus, FGFR2IIIb is expressed on epithelial cells but
not on cells of hematopoietic origin [18]. KGF is ap-
proved by the U.S. Food and Drug Administration
for the prophylaxis of oral mucositis in patients receiv-
ing high-dose therapy, including myeloablative condi-
tioning associated with HSCT.
KGF administration prior to cyclophosphamide,
irradiation, or dexamethasone increases thymic cellu-
larity in young and old mice and peripheral T cell
numbers in aged mice [19].
Using KGF 2/2 mice as donors or hosts in trans-
plant experiments reveals that the KGF required for
postirradiation thymic recovery is produced by host
nonhematopoietic cells.
Thymopoiesis and peripheral T cell reconstitution
are enhanced following KGF pretreatment of
recipients prior to syngeneic and allogeneic HSCT
[19,20] (Figure 1). Furthermore, KGF administrationdecreases GVHD morbidity and mortality in alloge-
neic recipients [18]. Recent primate studies revealed
that KGF improved thymic-dependent T cell reconsti-
tution in rhesus monkeys following transplantation
[21]. Thymic architecture was restored, thymic output
increased, and naı¨ve T cell numbers elevated in the
KGF-treated group. The enhanced T cell reconstitu-
tion translated to an increase in peripheral T cell
function [21].
The above preclinical studies suggest that KGF
administration enhances T cell reconstitution. Clini-
cal studies are currently underway in allogeneic
HSCT patients to assess whether KGF administra-
tion will enhance T cell recovery in patients receiving
an allograft consisting of CD341 hematopoietic stem
cells.
Lymphoid Precursors
As mentioned above, Notch signaling is involved
in a variety of fetal and adult cellular differentiation
processes and lineage decisions required for the devel-
opment of a multicellular organism [22]. Activation of
the Notch1 pathway promotes T lineage commitment
of hematopoietic progenitors while blocking B cell de-
velopment, and has been implicated in several critical
steps during T cell differentiation including commit-
ment to ab versus gd T cell lineage, Th1 versus Th2
cell differentiation, and development of regulatory
T cells.
Culture systems utilizing Notch1 signaling can be
used for the in vitro development of T lineage cells at
various differentiation stages. These systems include
Delta1ex-IgG as described above and the OP9-DL1 sys-
tem, which uses a mouse bone marrow stromal cell line
transduced to express the Notch1 ligand Delta-like 1
(DL1) to coculture hematopoietic stem cells in the
presence of IL-7 and FLT3-ligand [23]. This system
can be modified for the generation of large
numbers of lymphoid progenitors committed to the
T lineage for adoptive immunotherapy. We recently
demonstrated that cotransplanted allogeneic OP9-
DL1-derived early T progenitors can mature in an im-
munosuppressed host, mediating immunity including
antitumor activity without causing GVHD [24], and
can even be transferred in the absence of allogeneic
stem cells to any immunosuppressed individual irre-
spective of MHC disparities for adoptive ‘‘off-the-
shelf’’ immunotherapy (unpublished data by van den
Brink and coworkers). Such cells also protect the thy-
mus from atrophy, which otherwise hinders future
lymphopoiesis, and can be geneticallymodified in vitro
for targeted immunotherapy. Notch-based culture
systems show promise for clinically applicable thera-
peutic use. Human cord blood and human adult BM
derived CD341 progenitor cells have been cultured
in these systems to generate human T cells [20].
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Improve Engraftment and Restoration of Immune
Competence Un Autologous and Allogeneic HSCT
Richard Boyd, Jayne Sutherland, Tracy Heng, Gabrielle Goldberg, Daniel Gray, Anne Fletcher, Natalie Seach,
Ann Chidgey
Monash University, Clayton, Victoria, AustraliaParadoxical to its importance in developing im-
munity and preventing disease, the thymus also un-
dergoes profound age-related degeneration as
a consequence of the natural aging process, beginning
early in life but becoming more prominent postpu-
berty. This subsequently results in over 90% loss of
thymus output from 30 years of age, and is the pri-
mary cause of increased levels of diseases including
cancer and severe infections in the aged. Ironically,
with aging there is also a steep increase in immune
dysfunction such as autoimmune diseases (eg, multi-
ple sclerosis, lupus, rheumatoid arthritis, sclero-
derma). The consequences of thymic atrophy
become even more paramount following immune in-
sult such as HIV and the standard cancer treatments
of chemotherapy and radiation therapy. Although
children can recover effective immunity by 6 monthsafter treatment, adults rarely attain new naı¨ve T cells,
and even this minor level can require several years. In
addition, it is clear that the bone marrow also de-
clines in function with age. The collective impact of
a highly compromised thymus and bone marrow is
manifest as high susceptibility to infection of adults
undergoing standard of care cancer treatments, par-
ticularly myeloablative chemotherapy and HSCT.
To be able to reverse in particular the thymus aging
process, and also that of the bone marrow, thus rep-
resents 1 of the great challenges of modern medicine;
it would have a major impact in the treatment of
some of the most important diseases in the clinic.
Our research over the past 3 decades has focussed
on how the thymus develops, functions, and degener-
ates. Recognizing that steroids are the natural enemy
of the immune system, we are now able to reverse theFigure 2. Sex steroids are key to the degradation of the adult immune system and the immune system can be rejuvenated after regrowth of the
thymus.
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the body’s own endogenous recuperative mechanisms
to be reactivated. Accordingly, we have shown that in-
hibition of sex steroids results in a profound rejuvena-
tion of thymus function with extensive replenishment
of the T cell pool. This can be achieved in males and
females by surgical or biochemical (LHRH/GnRH)
means. The latter hormone treatment is fully revers-
ible, and is currently used as standard of care in sex hor-
mone exacerbated conditions such as prostate and
breast cancer. The intrathymic thymic events are first
manifest as an increase in the TN populations includ-
ing enhance proliferation of the early thymic pro-
genitor (ETP) subset by day 5 postcastration [25].
Subsequently, all thymocyte subpopulations increase
numerically, including the mature SPs in the medulla,
but in a homeostatically controlled manner with no
major proportional changes within the subsets. Thy-
mic rejuvenation is not restricted to theT cell compart-
ment.Wehave shownby gene chip analysis that thymic
stromal cells undergo marked alterations in expression
profiles within 24 hours. Thymic epithelial cells (TEC)
begin to upregulate MHC class II (which is decreased
with aging) by 5 days. The TEC proliferate by days
7-10, marginally lagging behind the T cells. There is
also a proportional increase in medullary thymic
epithelial cells (mTEC), again reversing changes con-
sequential to aging [26]. The cellular basis to the
TEC recovery is unclear, but collective evidence sug-
gest cells expressing low levels of MHC class II and
the cortical (cTEC) and mTEC markers Ly51/6C3
andUEA-1, respectively,maybe of precursor potential.
The increased thymopoiesis is reflected in renewed ex-
port of naı¨ve T cells to the periphery, reversing the de-
cline in CD4:CD8 ratio with age and restoring full
immune competence of the aged animal to viral and re-
sistance to transplantable tumours, to levels equivalent
to the young [27].
A fundamental feature of the thymic recovery was
the input of bone marrow-derived progenitor cells.
Sex steroid ablation increased the levels of bone mar-
row HSC and CLP and reversed the age-related bias
toward myelopoiesis, and improved the status of
bone marrow stromal cells forming the endosteal and
vascular niches. One important consequence of the im-
proved bone marrow and thymus was the enhanced
recovery of the immune system following ablation by
chemotherapy and radiotherapy. It also greatly
enhanced the recovery from myeloablative condition-
ing and the efficacy of autologous and allogeneic
HSCT [28,29]. The clinical applicability of LHRH
therapy to address immune deficiency was shown in
prostate cancer patients who had strong evidence of re-
newed thymic output 4 months after onset of LHRH
agonist therapy.
Collectively, the preclinical data and that from
the prostate cancer patients formed the basis to theprotocol for a pilot phase II clinical trial on patients
with hematologic malignancies (acute leukemia,
chronic leukemia, lymphoma, multiple myeloma) or
nonmalignancies myelodysplasia (1 patient) and aplas-
tic anemia (4 patients). Eighty patients in total (40 con-
trol, 40 LHRH treated, nonrandomized), male and
female, aged 17-69 were included in the trial. LHRH
was given over 4 months, beginning approximately
3 weeks prior to transplant, timed to induce castration
levels of sex steroids at the time of transplant. Patients
weremonitored for 12months. LHRH increasedHSC
engraftment (day 9 for allogeneic and day 10 for autol-
ogous) in both transplant groups, but the most signif-
icant finding was the restoration of naı¨ve CD41 T cell
production from 6 months in the allogeneic group
and 9-12 months in the autologous group. This
involved a full spectrum of T cell spectratypes. The
increase in naı¨ve T cells was demonstrated phenotyp-
ically and confirmed by TREC analysis.
This provides a fundamentally new approach to
overcoming the immunodeficiency caused by thymic
atrophy in adults requiring HSCT, and has immediate
applications to the development of new therapies aimed
at improving vaccines to infections and cancer, AIDS,
autoimmune diseases, and transplantation tolerance.
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